Success Metrics

Clinical Success Rate
75.0%

Based on 9 completed trials

Completion Rate
75%(9/12)
Active Trials
0(0%)
Results Posted
11%(1 trials)
Terminated
3(16%)

Phase Distribution

Ph phase_1
5
26%
Ph not_applicable
2
11%
Ph phase_2
7
37%
Ph phase_3
5
26%

Phase Distribution

5

Early Stage

7

Mid Stage

5

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
5(26.3%)
Phase 2Efficacy & side effects
7(36.8%)
Phase 3Large-scale testing
5(26.3%)
N/ANon-phased studies
2(10.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

9 of 12 finished

Non-Completion Rate

25.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

19

all time

Status Distribution
Completed(9)
Terminated(3)
Other(7)

Detailed Status

Completed9
unknown7
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
19
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (26.3%)
Phase 27 (36.8%)
Phase 35 (26.3%)
N/A2 (10.5%)

Trials by Status

unknown737%
completed947%
terminated316%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT02899221Not Applicable

Hyperthermia and High Dose Rate Radiation Therapy in Treating Patients With Recurrent Prostate Cancer After Radiation

Completed
NCT03955640Phase 1

Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences

Terminated
NCT01896778Not Applicable

Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer

Completed
NCT00002974Phase 2

Whole-Body Hyperthermia Plus Chemotherapy in Treating Patients With Advanced Sarcoma

Completed
NCT00769405Phase 3

Systemic Chemotherapy With or Without Intraperitoneal Chemohyperthermia in Treating Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer

Completed
NCT00346229Phase 1

Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer

Terminated
NCT00002973Phase 2

Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma

Completed
NCT00020007Phase 1

Paclitaxel and Hyperthermic Perfusion in Treating Patients With Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

Completed
NCT00024271Phase 2

Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer

Unknown
NCT00003052Phase 3

Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma

Completed
NCT00085631Phase 3

Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer

Terminated
NCT01094964Phase 3

Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer

Unknown
NCT00008112Phase 2

Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer

Unknown
NCT00045461Phase 2

Combination Chemotherapy With or Without Whole-Body Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Unknown
NCT00061867Phase 1

Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer

Completed
NCT00020501Phase 3

Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Completed
NCT00082862Phase 2

Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer

Unknown
NCT00004063Phase 1

Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer

Unknown
NCT00003135Phase 2

Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer

Unknown

All 19 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
19